PDSB
PDS Biotechnology Corporation
NASDAQ · Healthcare · Biotechnology · US
$0.22
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +16.2%
- EBIT
- +18.8%
- EPS
- +31.2%
- Free cash flow
- +51.2%
- Operating cash flow
- +51.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +71.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +10.2%
- EBIT
- +13.2%
- Net income
- +8.3%
- EPS
- +28.2%
- Free cash flow
- +20.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026